These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35698880)

  • 1. The cost-effectiveness of newborn screening for spinal muscular atrophy.
    Landfeldt E
    Dev Med Child Neurol; 2023 Jan; 65(1):8-9. PubMed ID: 35698880
    [No Abstract]   [Full Text] [Related]  

  • 2. Ontario Newborn Screening for Spinal Muscular Atrophy: The First Year.
    Kernohan KD; McMillan HJ; Yeh E; Lacaria M; Kowalski M; Campbell C; Dowling JJ; Gonorazky H; Marcadier J; Tarnopolsky MA; Vajsar J; Mackenzie A; Chakraborty P
    Can J Neurol Sci; 2022 Nov; 49(6):821-823. PubMed ID: 34620260
    [No Abstract]   [Full Text] [Related]  

  • 3. Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy.
    Lin PJ; Yeh WS; Neumann PJ
    Pediatr Neurol; 2017 Jan; 66():69-75. PubMed ID: 27769729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximising returns: combining newborn screening with gene therapy for spinal muscular atrophy.
    Gillingwater TH
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1252. PubMed ID: 34321342
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.
    Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE
    J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Testing for Patients with Spinal Muscular Atrophy.
    Brandsema JF; Gross BN; Matesanz SE
    Clin Lab Med; 2020 Sep; 40(3):357-367. PubMed ID: 32718505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correspondence on: "Discrepancy in Spinal Muscular Atrophy Incidence findings in newborn screening programs: the influence of carrier screening?" by Kay et al.
    Dangouloff T; Boemer F; Caberg JH; Servais L
    Genet Med; 2020 Nov; 22(11):1913-1914. PubMed ID: 32601389
    [No Abstract]   [Full Text] [Related]  

  • 8. 244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands.
    Dangouloff T; Burghes A; Tizzano EF; Servais L;
    Neuromuscul Disord; 2020 Jan; 30(1):93-103. PubMed ID: 31882184
    [No Abstract]   [Full Text] [Related]  

  • 9. Newborn screening for spinal muscular atrophy.
    Nishio H
    Lancet Child Adolesc Health; 2023 Mar; 7(3):146-147. PubMed ID: 36669517
    [No Abstract]   [Full Text] [Related]  

  • 10. Newborn screening for spinal muscular atrophy: Anticipating an imminent need.
    Phan HC; Taylor JL; Hannon H; Howell R
    Semin Perinatol; 2015 Apr; 39(3):217-29. PubMed ID: 25979781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for spinal muscular atrophy: an impetus for newborn screening.
    EBioMedicine; 2021 Jul; 69():103507. PubMed ID: 34315607
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands.
    Velikanova R; van der Schans S; Bischof M; van Olden RW; Postma M; Boersma C
    Value Health; 2022 Oct; 25(10):1696-1704. PubMed ID: 35963838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn infant screening for spinal muscular atrophy: Chances and challenges.
    Mueller-Felber W
    Dev Med Child Neurol; 2022 May; 64(5):535. PubMed ID: 35156200
    [No Abstract]   [Full Text] [Related]  

  • 14. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis.
    Shih ST; Farrar MA; Wiley V; Chambers G
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1296-1304. PubMed ID: 34321343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating neonatal spinal muscular atrophy: A 21st century success story?
    Tizzano EF
    Early Hum Dev; 2019 Nov; 138():104851. PubMed ID: 31604576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal muscular atrophy: newborn and carrier screening.
    Prior TW
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):23-36, Table of Contents. PubMed ID: 20494255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A call to introduce newborn screening for spinal muscular atrophy (SMA) in Scotland.
    Gillingwater TH; McWilliam C; Horrocks I; McWilliam K; Hamilton M; Fletcher E; Williams N; Smith S; Parson SH
    Scott Med J; 2022 Feb; 67(1):46-47. PubMed ID: 35147460
    [No Abstract]   [Full Text] [Related]  

  • 18. Impairment Experiences, Identity and Attitudes Towards Genetic Screening: the Views of People with Spinal Muscular Atrophy.
    Boardman FK; Young PJ; Griffiths FE
    J Genet Couns; 2018 Feb; 27(1):69-84. PubMed ID: 28664217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implementation of newborn screening for spinal muscular atrophy: the Australian experience.
    Kariyawasam DST; Russell JS; Wiley V; Alexander IE; Farrar MA
    Genet Med; 2020 Mar; 22(3):557-565. PubMed ID: 31607747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go.
    Dangouloff T; Vrščaj E; Servais L; Osredkar D;
    Neuromuscul Disord; 2021 Jun; 31(6):574-582. PubMed ID: 33985857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.